CAR-T cell therapies have demonstrated tremendous success in relapsed or refractory haematological malignancies. Now therapeutics companies and academics alike are racing to break through the barrier of solid tumours, taking imaginative approaches to overcome the numerous obstacles in the way of turning a hugely variable starting material into an armed and precisely targeted weapon against cancer. Sophie Lutter at OXGENE analyses an end-to-end solution to accelerate CAR-T cell development from concept to clinic.

Extract:

An End-to-End Solution to Accelerate CAR-T Cell Development from Concept to Clinic

CAR-T cell therapies have demonstrated tremendous success in relapsed or refractory haematological malignancies. Now therapeutics companies and academics alike are racing to break through the barrier of solid tumours, taking imaginative approaches to overcome the numerous obstacles in the way of turning a hugely variable starting material into an armed and precisely targeted weapon against cancer. But building a biologic is a team effort, so while therapeutics companies focus on perfecting their scientific approach, partnering with a contract testing development and manufacturing organisation (CTDMO) can help streamline their preclinical and manufacturing processes, and accelerate their journey to the clinic.

Leveraging the Power of the Immune System to Treat Advanced Cancers

TiCARos Therapeutics has leveraged the expertise of their team of immunologists from Seoul National University, College of Medicine to develop a promising pipeline of next generation immunotherapies for intractable haematologic malignancies and advanced solid tumours. TiCARos’ mission is to create medication based on science. TiCARos was founded by two leading T-cell immunologists, who have built a team with a deep passion for innovative science and immunology. Their strength is in leading-edge approaches to new CAR-T cell therapies. Since its foundation, TiCARos has established active collaborations with the renowned institutions Seoul National University College of Medicine and National Cancer Center, with which their founders have strong ties.

TiCARos’ cutting-edge technology platforms include CLIP CAR Technology, a strategy to stabilise the connection between CAR-T cells and antigen presenting cells, and CONVERTER CAR Technology, a strategy converting an inhibitory signal of CTLA-4 to an activating signal of CD28 in T cells by using CTC28 chimera, which potentiates CAR-T activity without a corresponding increase in side effects.

Click the download button below to read the complete version of ‘An End-to-End Solution to Accelerate CAR-T Cell Development from Concept to Clinic’ by Sophie Lutter at OXGENE